Hypertension and coronary artery disease

Saoud Tariq Etaiwi, Dana Essam Asali, Nasser Ali Aljalfan, Esam Mousa Othman Aqeeli, Mohamed Ahmed Mohamed, Ali Nassir Bumejdad, Fatimah Assad Aljabri, Hamzah Mohammed Alarfaj, Wed Ahmed Alsubhi

Abstract: In this article, we will discuss the relationship between CAD and hypertension, also we will review both nonpharmacological therapy and the different classes of medications and their benefits in the management of hypertensive individuals with CAD. We performed comprehensive search using biomedical databases; Medline, and Embase, for studies concerned with Hypertension and coronary artery disease published with English language up to, October 2017. Hypertension is a significant threat factor for coronary artery disease. Hypertension has been revealed to increase endothelial injury, therefore hindering the synthesis of nitric oxide and causing inflammation resulting in atherosclerosis. The common objective of using antihypertensive therapy in individuals with HTN and CAD is to prevent morbidity and death, and reduce negative results such as myocardial infarction, stroke or death. Furthermore, an essential goal to achieve as the case with any type of treatment is health-related quality of life and subjective well-being. Numerous randomized controlled trials, including the International Verapamil-Trandolapril Study (INVEST), have shown that CCBs and ACE preventions were medically as effective as b-blockers and diuretic therapy in hypertensive CAD patients. Moreover, the increasing occurrence of elderly hypertensive persons with CAD represents an extra challenge in management.

Introduction:

Cardiovascular (CV) disease, particularly atherosclerotic coronary artery disease (CAD) is a global health epidemic. One of the well-known significant danger factors for CAD is hypertension (HTN). Moreover, CAD and systemic vital HTN are age-dependent threat factors for damaging occasions [1]. HTN has been shown to create endothelial injury leading to a cascade of events that moderate the advancement of atherosclerosis. There are numerous research studies that confirm that reduced high blood pressure (BP) is helpful for people with CAD by decreasing the threat of stroke by roughly 40%, myocardial infarction by 20-25% and heart failure by 50% [2], [3].There are many classes of antihypertensive medicines that assist reduced BP in individuals with CAD and HTN. The number and sorts of these medicines has boosted substantially to over 125 representatives [4].Existing guidelines, based largely on consensus point of view, such as the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7), European Society of Hypertension (ESH) 2007 and the British Hypertension Society (BHS) suggest the therapy of high-risk individuals with HTN and concomitant diabetes mellitus (DM), peripheral artery condition and

CAD to an objective BP of less than 130/80 mmHg. The major emphasis of treatment with these classes of medications is to avoid or minimize the incidence of coronary infarction, congestive heart failure, end-stage kidney illness, stroke and death. In this post, we will certainly assess both nonpharmacological therapy and the different classes of medications and their benefits in the management of hypertensive individuals with CAD.

In this article, we will discuss the relationship between CAD and hypertension, also we will review both nonpharmacological therapy and the different classes of medications and their benefits in the management of hypertensive individuals with CAD.

Methodology:

We performed comprehensive search using biomedical databases; Medline, and Embase, for studies concerned with Hypertension and coronary artery disease published with English language up to, October 2017. keywords used in our search through the databases were as; “Hypertension”, “coronary artery disease”, “Pathogenesis”. More relevant articles were recruited from references lists scanning of each included study.

Discussion:

- **Epidemiology**

In the Global Burden of Disease research, high blood pressure (BP) was the leading single risk element globally, making up 9.4 million fatalities and 7.0 % of worldwide disability-adjusted life years (DALYS) in 2010 [5].High blood pressure is among the most significant risk elements worldwide, which with each other represent 90 % of the population's attributable risk for myocardial infarction in males and for 94 % in women [6].In a large meta-analysis, based on 61 potential observational researches involving one million adults without previous vascular illness,

the threat for fatality from ischemic heart disease was most affordable at 115 mmHg systolic BP (SBP) and 75 mmHg diastolic BP (DBP). To these limitations, a 20-mmHg reduced SBP was related to a 33- 50 % lower threat for fatality from ischemic heart disease throughout any age groups from 40 to 89 years and throughout both sexes [7]. Lately, the organization of BP with different symptoms of cardiovascular disease (including steady angina, unstable angina, myocardial infarction, anonymous coronary artery disease (CAD) death, heart failure, and cardiac arrest/sudden cardiac death) was compared amongst 1.25 million primary care patients in the UK aged 30 years and older, who were initially devoid of cardiovascular disease. The most affordable risk for all manifestations of CAD was observed in the lowest SBP group (90- 114 mmHg) and in the lowest DBP team (60- 74 mmHg) in patients aged 30- 79 years. In patients > 80 years, the threat for stable and unstable angina, myocardial infarction, and heart failure was additionally lowest in the lowest SBP team (90- 114 mmHg). The risks for unheralded CAD death and cardiac arrest/sudden cardiac fatality were not closely related to SBP in these older patients. When it come to DBP in the oldest patients (> 80 years), the dangers for almost all cardiac endpoints (with the exception of cardiac arrest) were not carefully relevant. Although isolated diastolic and systolic- diastolic hypertension are the more widespread subtypes of hypertension in individuals up to the age of 50, isolated systolic hypertension is most frequent in the senior. In the Framingham research, it was shown that in patients aged < 50 years, DBP was the best predictor of CAD. The age group 50- 59 years was a change area, where SBP, DBP, and pulse pressure (PP: SBP minus DBP) were equivalent forecasters of CAD. From 60 years old on, DBP correlated negatively with CAD, to ensure that PP was the strongest predictor of CAD. Likewise, in a big French population, males with systolic hypertension were at a greater risk when their DBP was listed below normal than when they had a mildto-moderate rise in DBP [8].The very same is true when 24-h blood pressure surveillance is used, as lately recommended by the Austrian Society of Hypertension: 24-h PP is s a strong independent forecaster of cardiac, primarily coronary events [9].

- **Pathogenesis of CAD: the importance of HTN**

The etiology of HTN causes major systemic results bring about end-organ damage as shown in Figure 1. HTN has been shown to create lowered vascular compliance and endothelial injury.

Endothelial injury has been just one of the major systems in the pathogenesis of atherosclerosis and CAD. Furthermore, endothelial injury impairs the synthesis of the potent vasodilator, nitric oxide. This subsequently results in more inflammation and thrombosis through reactive oxygen varieties and numerous inflammatory markers [10]. Consequently, endothelial injury brought on by HTN causes a cascade of occasions, which develop the foundation for CAD. One more significant system of HTN triggering CAD is through the renin- angiotensin- aldosterone system (RAAS). Studies have shown that angiotensin II rises BP and the generation of reactive oxygen species, which contribute to opposing the advantageous vascular effects of nitric oxide [11]. Angiotensin II has been shown to increase arterial wall stiffness, thus harming vascular conformity [12]. Additionally, angiotensin II contributes to the growth of insulin resistance and stimulates the production of proinflammatory particles that create vascular inflammation and coagulopathy [11].Hypertension has likewise been acknowledged with enhanced sympathetic activity. Sympathetic hyperactivity causes raised plasma norepinephrine levels and enhanced BP, heart rate, cardiac outcome and renal tubular sodium reabsorption. These modifications create a vicious cycle, with a subsequent increase in RAAS task further leading to HTN.

- **Link between Hypertension and Coronary Heart Disease**

The pathophysiological link between hypertension and CHD can be described under two major pathways as described below and shown in Figure 1.



Figure 1. Pathophysiological link between hypertension and coronary heart disease.

Atherogenesis

The physical effect of high BP can trigger endothelial injury. Harmed endothelium lead to impairment in the synthesis and the release of the potent vasodilator-nitric oxide and promotes the accumulation of responsive oxygen types and various other inflammatory aspects which moderate the growth of atherosclerosis, thrombosis, and vascular occlusion. This inflammatory

process is a famous attribute in the pathogenesis of both hypertension and atherosclerosis [13].Some mechanisms such as the rennin-angiotensin-aldosterone system (RAAS) and the supportive nerves that preserve hypertension are also those that advertise atherosclerosis. Angiotensin II boosts BP and helps with development of atherosclerosis with vasoconstrictive and vascular improvement effects. This monitoring brought about the suggestion that some antihypertensive agents such as angiotensin-converting enzyme (ACE) inhibitors may have valuable impacts on atherosclerosis and CHD in addition to their BP decreasing result [14].

Increased Afterload and Left Ventricular Hypertrophy

High blood pressure on its own could create myocardial ischemia in the lack of CHD. Enhanced afterload as a result of high blood pressure could result in considerable left ventricular hypertrophy (LVH), which may hinder ventricular leisure and compromise coronary blood circulation during diastole. Although hereditary elements have been associated with LVH, chronic unrestrained hypertension appears to be the significant cause [15].Research has revealed that LVH reduces coronary flow reserve [16] and separately anticipates future CHD, HF, stroke, and sudden cardiac death.

- **Treatment**

Nonpharmacological Interventions

Nonpharmacological treatments ought to be encouraged in all people with hypertension. Exercise boosts cardiac function, decreases BP and cardiac afterload by a variety of systems, including reduced arterial rigidity [17].Research has revealed that physical activity predicts the probability of CVS disease past that clarified by the generally determined cardiometabolic danger factors

[18].Although the system is not entirely clear, evidence indicates that exercise boosts coronary artery flow reserves in CHD patients and pathophysiological mechanisms that are potentially vital in creating CHD have been linked to exercise. Therefore, regular exercise is recommended in all people with hypertension and CHD.

Studies have also revealed that different way of living behaviors, consisting of undesirable diet, physical inactivity, and smoking cigarettes, promote the development and clinical manifestations of CHD [19].Therefore, lifestyle changes and adoption of healthful behaviors are equally essential in the management of hypertension and CHD. Special focus must be given to weight loss, diet control, salt intake, alcohol intake, cigarette smoking, and stress management.

Pharmacological Treatment

Pharmacological therapy is inescapable in high-risk populations such as those with CHD, although lifestyle changes alone may be sufficient in the basic population with prehypertension. The recommended target BP for individuals with CHD or CHD equivalents: diabetes mellitus, chronic kidney illness, outer arterial condition, carotid artery condition, and stomach aortic aneurysm is <130/80 mm Hg [20].Although several antihypertensive agents exist, it is not completely clear whether all antihypertensive agents are similarly effective in avoiding or decreasing development of CHD. Below, we discuss each agent and give the evidence on behalf of their use.

Beta-Blockers

The treatment of high blood pressure in CHD patients ought to start with β-blockers as first-line treatment, unless contraindicated [21].Relative contraindications to their use consist of

hypotension, extreme bronchospastic lung disease, decompensated HF, sinus or atrioventricular node dysfunction, and serious peripheral vascular disease. Likewise, diabetic patients with substantial history of hypoglycemic episodes ought to utilize β-blockers with fantastic care as a result of the threat of masking signs of hypoglycemia.

β-blockers are heterogenous class of representatives with varying pharmacological impacts. The cardioselective β-blockers without innate sympathomimetic activity are normally liked. These agents decrease myocardial oxygen intake and heart rate and improve coronary circulation by increasing diastolic filling up period. Amongst patients with both acute myocardial infarction (MI) and high blood pressure, β-Blockers have been shown to restrict infarct size, boost survival, and decrease the threat of reoccurring MI and the occurrence of unexpected cardiac fatality, which is secondary to fatal arrhythmias [22].While metoprolol, carvedilol, and bisoprolol were revealed to boost outcomes in HF patients, atenolol-based treatment was located to be inferior to amlodipine-based treatment in decreasing CVS events in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Similarly, a substudy of ASCOT, the Conduit Artery Function Evaluation (CAFÉ), showed that Atenolol was less reliable in minimizing systolic BP and cardiac afterload compared to amlodipine, which possibly could be explained by the observation of boosted arterial stiffness and aortic wave reflections in patients utilizing beta-blockers [23].For this reason, in the absence of MI, CHD, or HF, using β-blockers as first-line therapy for high blood pressure is controversial and not supported.

Calcium Channel Blockers

Long-acting dihydropyridines calcium channel blockers (CCBs), amlodipine, and nifedipine can be contributed to the basic routine if BP stays elevated or angina proceeds while on β-blocker

therapy. The nondihydropyridine agents, diltiazem and verapamil, can likewise be substituted for β-blocker when contraindications exist or negative effects create [24].Although nondihydropyridine CCBs can be utilized as antianginal in combination with a β-blocker, there is connected threat of extreme bradycardia or atrioventricular block. As a result, if a CCB is required in addition to β-blocker to control angina or BP, it must be a long-acting dihydropyridine CCB. These agents decrease BP by triggering vasodilation and decreasing outer resistance and wall tension, hence reducing myocardial O2 need. They additionally raise myocardial O2 supply by dilating coronary arteries.

Nitrates

Nitrates have not been shown to be of substantial use in hypertension therapy; however, they are suggested for acute relief of angina or treatment of chronic angina which can not be controlled with β-blockers and CCBs. The records of 2 large tests contrasting nitrates with placebo showed no difference in mortality with the use of nitrates [25]. Therefore, nitrates are not suggested to minimize cardiac events however only to alleviate angina, control BP, and handle pulmonary congestion. Nitrates combined with hydralazine have survival benefit in chosen HF patients. However, individuals taking nitrates should be recommended not to use phosphodiesterase inhibitors such as sildenafil, as the combination of both may create severe hypotension.

Angiotensin-Converting Enzyme

ACE inhibitors are suggested for usage in all patients after MI. 2 significant tests, the European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease (EUROPA) and Heart Outcome Prevention Evaluation (HOPE) research, showed the

cardioprotective effect of ACE prevention in hypertensive CHD patients [26].In the EUROPA research, 12,218 patients were randomized to therapy with an ACE prevention (perindopril) or placebo. People in the perindopril team had considerably much less MI, CVS death, or cardiac arrest [26].The HOPE study involved 9,297 patients with CVS risk variables, that were randomized to ramipril or placebo. Around fifty percent of the research populace had hypertension. Ramipril therapy was associated with tiny (3/2 mm Hg) reduction in BP yet considerable reduction in CVS fatality, stroke, and MI. These cardioprotective effects were initially thought to be independent of BP control, up until a subgroup evaluation of the HOPE trial revealed a considerable decrease in 24-hour ambulatory BP with ramipril that was not found generally test that measured only office BP [27].

Angiotensin-Receptor Blockers

In people who are ACE inhibitor intolerant or allergic, angiotensin receptors blockers (ARBs) have been shown to be an efficient option in the therapy of hypertension, CHD, and HF. Emerging information show up to sustain the use of ARBs in MI. In the VALIANT research study, the ARB, valsartan was as reliable as captopril in patients at high risk of CVS occasions after MI [28].Amongst 15,245 hypertensive patients that were enrolled in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) test, the ARB, valsartan, and CCB, amlodipine had similar primary protection against CVS events. Hence, ARB appears to be a good substitute in those individuals where ACEI is contraindicated.

Diuretic

The ALLHAT trial plainly showed the benefit of thiazide diuretic in the treatment of high blood pressure, although there are concerns regarding the contribution of the metabolic impacts of

thiazide to CHD danger [29].The performance of thiazide in controlling BP and preventing CVS occasions has been shown in a number of research studies [30], however their use in the setup of acute MI is not encouraged and if at all required, should be done with care. While there is an ongoing argument over whether the medical benefits observed with thiazide-type diuretic are medicine certain, it is not unreasonable to presume that there is a "class impact," given the high level of homogeneity in the system of action of this team of antihypertensive agents.

Conclusion:

Hypertension is a significant threat factor for coronary artery disease. Hypertension has been revealed to increase endothelial injury, therefore hindering the synthesis of nitric oxide and causing inflammation resulting in atherosclerosis. The common objective of using antihypertensive therapy in individuals with HTN and CAD is to prevent morbidity and death, and reduce negative results such as myocardial infarction, stroke or death. Furthermore, an essential goal to achieve as the case with any type of treatment is health-related quality of life and subjective well-being. Numerous randomized controlled trials, including the International Verapamil-Trandolapril Study (INVEST), have shown that CCBs and ACE preventions were medically as effective as b-blockers and diuretic therapy in hypertensive CAD patients. Moreover, the increasing occurrence of elderly hypertensive persons with CAD represents an extra challenge in management. Researches have reiterated caution in decreasing BP to below 130 mmHg owing to increased morbidity and mortality. Nonpharmacological therapy such as

weight loss, exercise and cessation of smoking should be the first approach to all patients with hypertension.

Reference:

1. Denardo SJ, Gong Y, Nichols WW et al. Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy. Am. J. Med. 123(8), 719–26 (2010).
2. Ismail H, Mitchell R, McFarlane S, Makaryus AN. Pleiotropic effects of inhibitors of the RAAS in the diabetic population: above and beyond blood pressure lowering. Curr. Diab. Rep. 10, 32–36 (2010).
3. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 28(12), 1462–1536 (2007).
4. Black HR, Greenberg BH, Weber MA. The foundation role of b blockers across the cardiovascular disease spectrum: a year 2009 update. Am. J. Med. 123(11), S2 (2010).
5. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of DiseaseStudy 2010. Lancet. 2012;380:2224–60.
6. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarctionin 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–52.
7. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies C.. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–13.
8. Benetos A, Thomas F, Safar ME, Bean KE, Guize L. Should diastolic and systolic blood pressure be considered for cardiovascular risk evaluation: a studyinmiddle-agedmen andwomen. JAmCollCardiol. 2001;37:163–8.

9. Verdecchia P, Schillaci G, Reboldi G, Franklin SS, Porcellati C. Different prognostic impact of 24-hour mean blood pressure and pulse pressure on stroke and coronary artery disease in essential hypertension. Circulation. 2001;103:2579–84.
10. Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Ann. Intern. Med. 139(9), 761–776 (2003).
11. Griendling KK, Ushio-Fukai M, Lassegue B, Alexander RW. Angiotensin II signaling in vascular smooth muscle: new concepts. Hypertension 29, 366–373 (1997).
12. Dzau VJ. Theodore Cooper Lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 37(4), 1047–1052 (2001).
13. Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Annals of Internal Medicine. 2003;139(9):761–776.
14. Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. Journal of Hypertension. 2005;23(1, supplement):S9–S17.
15. Levy D, Anderson KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham heart study. Annals of Internal Medicine. 1988;108(1):7–13.
16. Frohlich ED. Hypertension, left ventricular hypertrophy, and coronary flow reserve. Advances in Experimental Medicine and Biology. 1997;432:253–262.
17. Vaitkevicius PV, Fleg JL, Engel JH, et al. Effects of age and aerobic capacity on arterial stiffness in healthy adults. Circulation. 1993;88(4):1456–1462.
18. McGuire KA, Janssen I, Ross R. Ability of physical activity to predict cardiovascular disease beyond commonly evaluated cardiometabolic risk factors. American Journal of Cardiology. 2009;104(11):1522–1526.
19. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation. 1999;99(16):2192–2217.
20. Okrainec K, Banerjee DK, Eisenberg MJ. Coronary artery disease in the developing world. American Heart Journal. 2004;148(1):7–15.
21. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: executive summary: a report of the ACC/AHA Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines

for the Management of Patients With Acute Myocardial Infarction) Circulation. 2004;110:588–636.

22. Viskin S, Kitzis I, Lev E, et al. Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice. Journal of the American College of Cardiology. 1995;25(6):1327–1332.
23. Olafiranye O, Qureshi G, Salciccioli L, Weber M, Lazar JM. Association of beta-blocker use with increased aortic wave reflection. Journal of the American Society of Hypertension. 2008;2(2):64–69.
24. Rosendorff C. Calcium antagonists in the treatment of hypertension in patients with ischaemic heart disease. Expert Opinion on Pharmacotherapy. 2003;4(9):1535–1541.
25. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. The Lancet. 1995;345:669–685.
26. Fox KM, EURopean Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) The Lancet. 2003;362:782–788.
27. Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures:a HOPE substudy. Hypertension. 2001;38(6):E28–E32.
28. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. New England Journal of Medicine. 2003;349(20):1893–1906.
29. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension. 2004;43(5):963–969.
30. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP) Journal of the American Medical Association. 1991;265(24):3255–3264.